Additionally, structural modeling of PIWIL2 and SLC39A14-PIWIL2, which encodes a truncated form (tPIWIL2), and their interactions with downstream proteins, alongside the design of PIWIL2 inhibitory peptides, has further highlighted its potential as a therapeutic target in HCC, opening avenues for the development of PIWIL2-focused treatments. This evidence concerns the gene PIWIL2 and hepatocellular carcinoma.